Miochol-E is an injectable miotic pharmaceutical used during certain eye surgeries to constrict the pupil.
As per the agreement, Novartis will provide technical assistance to Bausch + Lomb to assist in the transfer of Miochol-E manufacturing.
Bausch + Lomb president of global pharmaceuticals Dan Wechsler said that closure of this acquisition is a terrific gain for Bausch + Lomb pharmaceuticals.
“Miochol-E not only continues to diversify our ophthalmic portfolio, it allows patients to continue to benefit from this well-known product,” Wechsler said.